2022年围手术期非小细胞肺癌免疫治疗研究进展

王长利; 岳东升; 陈晨

doi:10.12354/j.issn.1000-8179.2022.20221011

2022年围手术期非小细胞肺癌免疫治疗研究进展

doi: 10.12354/j.issn.1000-8179.2022.20221011

天津医科大学肿瘤医院肺部肿瘤科，国家恶性肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，天津市恶性肿瘤临床医学研究中心，天津市肺癌诊治中心（天津市300060）

详细信息

通讯作者:
王长利　wangchangli@tjmuch.com

计量
- 文章访问数: 269
- HTML全文浏览量: 51
- PDF下载量: 65
- 被引次数: 0
出版历程
- 收稿日期: 2022-07-07
- 录用日期: 2022-11-22
- 修回日期: 2022-11-22
- 网络出版日期: 2022-12-02

Advances in perioperative immunotherapy for non-small cell lung cancer in 2022

Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Lung Cancer Center, Tianjin 300060, China

More Information

Corresponding author: Changli Wang; E-mail: wangchangli@tjmuch.com

摘要

摘要: 近年来围手术期非小细胞肺癌（non-small cell lung cancer，NSCLC）免疫治疗成为研究热点，新辅助免疫治疗和辅助免疫治疗Ⅲ期NSCLC临床试验的成功证明了免疫治疗对于围手术期NSCLC患者的重要价值。2022年国内外报道和更新了多项围手术期NSCLC免疫治疗的临床研究，对该领域一些热点问题如是否可以带来生存获益，获益人群的筛选，替代终点的可靠性等尝试进行了回答，同时也引发了新的思考。本文对2022年围手术期NSCLC免疫治疗研究进展进行综述。
- 非小细胞肺癌 /
- 围手术期治疗 /
- 免疫治疗
Abstract: Perioperative immunotherapy for non-small cell lung cancer (NSCLC) has attracted increasing attention of researchers in recent years. The success of phase Ⅲ clinical studies of neoadjuvant and adjuvant therapies for NSCLC has demonstrated the value of immunotherapy. Numerous studies on perioperative NSCLC immunotherapy were reported and updated in 2022. These studies attempted to answer some critical issues, such as the possible survival benefits of immunotherapy, identification of the population it benefits, and reliability of surrogate endpoints. The results of these studies have triggered new perspectives on this therapeutic approach. In this article, we review the progress in research on perioperative immunotherapy for NSCLC in 2022.
- non-small cell lung cancer (NSCLC) /
- perioperative treatment /
- immunotherapy

HTML全文

参考文献(29)

[1]	Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survivalfor patients with advanced nonsmall-cell lung cancer treated withpembrolizumab: results from the phase Ⅰ KEYNOTE-001 study[J]. J Clin Oncol, 2019, 37(28):2518-2527. doi: 10.1200/JCO.19.00934
[2]	Martin R, Delvys RA, Andrew GR, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score≥50%[J]. J Clin Oncol, 2021, 39(21):2339-2349. doi: 10.1200/JCO.21.00174
[3]	Patrick MF, Jonathan S, Shun L, et al. Abstract CT003: Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs. chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial[J]. Cancer Res, 2021, 81(13_Suppl):CT003.
[4]	Heather AW, Nasser KA, Caicun Z, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2021, 39(15_suppl):abstr8500
[5]	Nicolas G, Jonathan S, Mariano P, et al. Abstract CT012: Nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) vs. chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): event-free survival (EFS) results from the phase 3 CheckMate 816 trial[J]. Cancer Res, 2022, 82(12_Suppl):CT012.
[6]	Mariano PP, Ernest N, Jose LG, et al. Nivolumab+chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial[J]. J Clin Oncol, 2022, 40(16_suppl):abstr8501.
[7]	Mariano P, Roberto S, Ernest N, et al. Progression free survival and overall survival in NADIM II study[J]. J Thorac Oncol, 2022, 17(9_suppl):S2 - S3.
[8]	Lin YB, Chen YH, Zhai WY, et al. PhaseIl trial of neoadjuvant tislelizumab with chemotherapy in stage IIB III non small cell lung cancer[J]. J Thorac Oncol, 2022, 17(9_Suppl):S287.
[9]	Cheng XY, Huang J, Zhou M. Clinical outcomes of neoadjuvant tislelizumab plus chemotherapy in resectable stage IIIA B NSCLC: a retrospective study[J]. J Thorac Oncol, 2022, 17(9_Suppl):S236-S237.
[10]	Wang T, Li L, Huang L, et al. Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2019, 37(15suppl):2556
[11]	Shan J, Liu Z, Du C, et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for stageⅢA～ⅢB(N2) potentially resectable squamous non-smallcelllungcancer(TACT). Int J Surg, 2022,103:106680.
[12]	Yan S, Chen J, Wang J, et al. Neoadjuvant toripalimab combination in patients with stage IIB IIIB NSCLC: a single arm, phase 2 trial (Renaissance Study)[J]. J Thorac Oncol, 2022, 17(9_Suppl):S288-S289.
[13]	Schuler MHH, Cuppens K, Ploenes T, et al. LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)[J]. Ann Oncol, 2022, 33(7_Suppl):S1404.
[14]	Tina C, García-Campelo R, Spicer J, et al. Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)[J]. Cancer Res, 2022, 82(12_Suppl):CT011.
[15]	Deutsch JS, Mathews AC, Thompson ED, et al. LBA50 analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816[J]. Ann Oncol, 2022, 33(7_Suppl):S1415-S1416.
[16]	Qiu FM, Fan JQ, Shao M, et al. Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): a randomized, single center, two-arm phase II trial.[J]. J Clin Oncol, 2022, 40(16_Suppl):abstr8500. doi: 10.1200/JCO.2022.40.16_suppl.8500
[17]	Mariano PP, Jonathan S, Janis MT, et al. Neoadjuvant nivolumab (NIVO)+platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): Association of pathological regression with event-free survival (EFS) in CheckMate 816[J]. J Clin Oncol, 2022, 40(17_Suppl):LBA8511. doi: 10.1200/JCO.2022.40.17_suppl.LBA8511
[18]	Rosner S, Reuss E J, Zahurak M, et al. Neoadjuvant nivolumab in early-stage non–small cell lung cancer (NSCLC): Five-year outcomes[J]. J Clin Oncol, 2022, 40(16_Suppl):abstr8537. doi: 10.1200/JCO.2022.40.16_suppl.8537
[19]	Ares LP, Brien MO, Mauer M, et al. Pembrolizumab versus placebo forearly-stage NSCLC Following complete resection and adjuvant chemotherapy when indicated: randomized, triple-blind, phase 3EORTC-1416-LCG/ETOP 8-15PEARLS/KEYNOTE-091 study[J]. Ann Oncol, 2022, 33(4):451-453. doi: 10.1016/j.annonc.2022.02.224
[20]	Garon EB, Lu S, Goto Y, et al. CANOPY-A: phase III study of canakinumab as adjuvant therapy in patients withcompletely resected non-small cell lungcancer[J]. Ann Oncol, 2022, 33(7_Suppl):S1414-1415.
[21]	O'Brien MER, Paz-Ares L, Jha N, et al. EORTC-1416-LCG/ETOP 8-15–PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use[J]. J Clin Oncol, 2022, 40(16_Suppl):abstr8512. doi: 10.1200/JCO.2022.40.16_suppl.8512
[22]	Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy inresected stage IB–IIIA non-small-cell lung cancer(IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308):P1344-1357.
[23]	Peters S, Besse B, Marreaud S, et al. PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB IIIA NSCLC: subgroup analysis of PEARLS/KEYNOTE 091[J]. Ann Oncol, 2022, 33(7_Suppl):971-972.
[24]	Xia L, Mei JD, Kang R, et al. Perioperative ctDNA-based molecular residual disease detection for non–small cell lung cancer: a prospectivemulticenter cohort study (LUNGCA-1)[J]. Clin Cancer Res, 2022, 28(15):3308-3317. doi: 10.1158/1078-0432.CCR-21-3044
[25]	Zhou C, das Thakur M, Srivastava MK, et al. IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs. best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC[J]. Ann Oncol, 2022, 32(7_Suppl):S1374.
[26]	Zhang JT, Liu SY, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer[J]. Cancer Discov, 2022, 12(7):1690-1701. doi: 10.1158/2159-8290.CD-21-1486
[27]	Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non–small-cell lung cancer treated with curative intent[J]. J Clin Oncol, 2022, 40(6):567-575. doi: 10.1200/JCO.21.01929
[28]	Mauguen A, Pignon JP, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data[J]. Lancet Oncol, 2013, 14(7):619-626. doi: 10.1016/S1470-2045(13)70158-X
[29]	Felip E, Altork N, Vallieres E, etal. IMpower010: overall survival interim analysis of a phase III study of atezolizumab vs bestsupportive care in resected NSCLC[J]. J Thorac Oncol, 2022, 17(9_suppl):S2.